Subscribe to RSS
DOI: 10.5482/HAMO-14-11-0064
Management of acquired haemophilia A
Management der erworbenen HämophilieThe authors are grateful to all participating centres of the GTH-AH 01/2010 study for their contribution. Funding for this study was obtained from GTH e. V. and by unrestricted educational grants from Novo Nordisk Pharma GmbH, Mainz, Germany, and Baxter Deutschland GmbH, Unterschleißheim, Germany.Publication History
received:
14 November 2014
accepted in revised form:
11 January 2014
Publication Date:
28 December 2017 (online)
Summary
Acquired haemophilia A (AHA) is caused by autoantibody inhibitors of coagulation factor VIII (FVIII : C). Recent onset of bleeds and isolated prolongation of the activated partial thromboplastin time (aPTT) are characteristic features of the disorder. Reduced FVIII : C activity and a detectable FVIII : C inhibitor in the Bethesda assay confirm the diagnosis. Patients should be referred to expert centres, whenever possible, and invasive procedures with a high risk of bleeding must be avoided, until haemostasis has been secured by adequate therapy.
Bypassing agents capable of inducing sufficient thrombin formation in the presence of FVIII : C inhibitors are treatment of choice, including currently available recombinant factor VIIa (NovoSeven™) and activated prothrombin complex concentrate (FEIBA™). These agents represent first line therapy to control acute or severe bleeds. To eradicate inhibitors, immunosuppressive treatment (IST) is indicated in patients with AHA. Glucocorticoids, cytotoxic agents and rituximab are most widely used. However, an ideal IST regimen has not been established so far. Adverse events of IST, including infections as the foremost cause death, are frequent complications in AHA.
Zusammenfassung
Die erworbene Hämophilie A wird durch Auto - antikörper gegen den Gerinnungsfaktor VIII (FVIII : C) verursacht. Eine neu aufgetretene Blutungsneigung und isolierte Verlängerung der aktivierten partiellen Thromboplastinzeit (aPTT) sind Hinweise auf die Erkrankung. Die Diagnose wird durch reduzierte FVIII : C-Aktivität und im Bethesda-Test nachweisbaren FVIII : C- Inhibitor bestätigt. Die Patienten sollten in erfahrenen Zentren behandelt werden. Invasive Prozeduren mit hohem Blutungsrisiko sind unbedingt aufzuschieben, bis die Hämostase durch adäquate Behandlung wieder gewährleistet ist.
Therapie der Wahl ist der Einsatz so genannter Bypass-Produkte, die auch in Anwesenheit von FVIII:C-Inhibitoren eine ausreichende Thrombinbildung bewirken. Zur Verfügung stehen gegenwärtig rekombinanter Faktor VIIa (NovoSeven®) und aktiviertes Prothrombinkomplex- Konzentrat (FEIBA®). Bei akuten oder schweren Blutungen haben sich diese Medikamente als Erstlinientherapie bewährt. Zur Eradikation des Inhibitors sollten Patienten mit erworbener Hämophilie eine immunsuppressive Therapie (IST) erhalten. Glucokortikoide, Zytostatika und Rituximab sind die am häufigsten eingesetzten Substanzen. Allerdings existiert bislang kein optimales IST-Regime. Unerwünschte Arzneimittelwirkungen der IST, vor allem Infektionen als häufigster Todesursache, sind oftmals auftretende Komplikationen bei Patienten mit erworbener Hämophilie.
-
References
- 1 Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A. Br J Haematol 2010; 148: 183-194.
- 2 Baudo F, Caimi T, de Cataldo F. Diagnosis and treatment of acquired haemophilia. Haemophilia 2010; 16: 102-106.
- 3 Knoebl P, Marco P, Baudo F. et al. Demographic and clinical data in acquired hemophilia A. J Thromb Haemost 2012; 10: 622-631.
- 4 Gheisari R, Bomke B, Hoffmann T. et al. Clinical features and outcome of acquired haemophilia A. Hämostaseologie 2010; 30: 156-161.
- 5 Baudo F, Collins P, Huth-Kuhne A. et al. Management of bleeding in acquired hemophilia A. Blood 2012; 120: 39-46.
- 6 Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A. Semin Thromb Hemost 2014; 40: 803-811.
- 7 Pengo V, Tripodi A, Reber G. et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 07: 1737-1740.
- 8 Tripodi A, Mancuso ME, Chantarangkul V. et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII. Clin Chem 2005; 51: 1883-1885.
- 9 Huth-Kuhne A, Baudo F, Collins P. et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-575.
- 10 Sumner MJ, Geldziler BD, Pedersen M. et al. Treatment of acquired haemophilia with recombinant activated FVII. Haemophilia 2007; 13: 451-461.
- 11 Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 1463-1467.
- 12 Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-173.
- 13 Holmstrom M, Tran HT, Holme PA. Combined treatment with APCC and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A. Haemophilia 2012; 18: 544-549.
- 14 McCain S, Gull S, Ahmad J. et al. Acquired hemophilia A as a cause of acute upper gastrointestinal hemorrhage. BMJ Case Rep. 2014: 2014.
- 15 Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002; 68: 307-309.
- 16 Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-1081.
- 17 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F. et al. Acquired haemophilia: review and metaanalysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
- 18 Collins P, Macartney N, Davies R. et al. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004; 124: 86-90.
- 19 Tiede A, Huth-Kuhne A, Oldenburg J. et al. Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland. Ann Hematol 2009; 88: 365-370.
- 20 Collins PW. Management of acquired haemophilia A. J Thromb Haemost 2011; 09 (Suppl. 01) 226-235.
- 21 Collins PW, Hirsch S, Baglin TP. et al. Acquired hemophilia A in the United Kingdom. Blood 2007; 109: 1870-1877.
- 22 Collins P, Baudo F, Knoebl P. et al. Immunosuppression for acquired hemophilia A. Blood 2012; 120: 47-55.
- 23 Collins P, Baudo F, Huth-Kuhne A. et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010; 03: 161.
- 24 Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-778.
- 25 Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica 2000; 85 (Suppl. 10) 64-68.
- 26 Zeitler H, Ulrich-Merzenich G, Hess L. et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol. Blood 2005; 105: 2287-2293.
- 27 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-203.
- 28 Tiede A, Klamroth R, Scharf RE. et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125: 1091-1097.
- 29 Barrow RT, Lollar P. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost 2006; 04: 2223-2229.
- 30 Lozier JN, Nghiem K, Lee M. et al. Acquired haemophilia A after stem cell transplant for sickle cell disease. Haemophilia 2014; 20: e185-e188.